Key result
Sequential chemotherapy regimens including R-miniCHOP, OR-GemOx, and Pola-BR successfully achieved complete remission in a 73-year-old male with primary cardiac diffuse large B-cell lymphoma.
Why the study?
Primary cardiac diffuse large B-cell lymphoma is a rare, clinically challenging extranodal lymphoma whose diagnosis and management are complicated by rarity and nonspecific symptoms.
Case Report (n=1)
Primary cardiac DLBCL can present with sick sinus syndrome and be successfully managed with tailored chemotherapy regimens like OR-GemOx and Pola-BR, highlighting the need for individualized treatment to balance efficacy and cardiotoxicity.
Alerts clinicians to primary cardiac DLBCL in unexplained masses with arrhythmias; leaves open standardized diagnostic and therapeutic approaches.
Background: Primary cardiac diffuse large B-cell lymphoma (DLBCL) is a rare but clinically challenging extranodal lymphoma. Diagnosis and management are often complicated due to its nonspecific symptoms and rarity. Case Report: We reported a case of a 73-year-old male who initially presented with chest pain, high fever, dizziness, and amaurosis. Preliminary diagnostic assessments suggested sick sinus syndrome, necessitating the implantation of a dual-chamber pacemaker, and revealed a large mass in the interatrial septum. An endomyocardial biopsy confirmed the diagnosis of primary cardiac DLBCL. Initial treatment with R-miniCHOP chemotherapy yielded a partial response. However, due to treatment-related complications (grade 4 neutropenia and pneumonia), a change in the therapeutic regimen to OR-GemOx chemotherapy was made, leading to complete remission. A year later, the patient experienced a relapse, requiring a salvage treatment of the Pola-BR chemotherapy regimen, which again resulted in complete remission. Additionally, this review examines an in-depth literature review on the management and therapeutic strategies for this entity, focusing on the treatment recommendations for relapse/refractory disease. Conclusion: Prompt diagnosis and effective management are crucial in treating primary cardiac DLBCL. While the emergence of new drugs has improved the prognosis by offering higher efficacy and fewer side effects, clinicians should be vigilant about potential cardiotoxicities.
No takes yet. Share an insight, caveat, or question.
Qiu et al. (2025) conducted a case report in Primary cardiac diffuse large B-cell lymphoma (DLBCL) with sick sinus syndrome (n=1). Sequential chemotherapy (R-miniCHOP, OR-GemOx, Pola-BR) was evaluated on Clinical remission. Sequential chemotherapy regimens including R-miniCHOP, OR-GemOx, and Pola-BR successfully achieved complete remission in a 73-year-old male with primary cardiac diffuse large B-cell lymphoma.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: